A single intraperitoneal injection (0.6 ml/kg) of dimethoxyethyl phthalate (DMEP) was given to groups of Wistar strain rats on day 10, 11, 12, 13 or 14 of gestation. Control rats received 0.6 ml/kg of physiological saline intraperitoneally.
Introduction
Plastics have become an integral part of our everyday lives. Phthalate esters are plasticizers widely used in the manufacture of plastics (1) . In the United States, an estimated one billion pounds of phthalate esters are produced annually (2, 
3).
There are approximately 20 different phthalate compounds sold as vinyl plasticizers, and one of the most toxic of these is dimethoxyethyl phthalate (DMEP) (1) (2) (3) ping materials (4, 5) , and a variety of medical and paramedical devices, including heart valves, vascular grafting material, intrauterine devices, catheters, dialyzing units, blood sets and disposable syringes. Residues of phthalates have been found in milk (6) , human tissues and blood plasma (7) , bovine tissues and the hearts of dogs, rabbits and rats (8) . Phthalates, in general, are colorless, high-boiling liquids, soluble in organic solvents but immiscible in water, and they are degraded very slowly in the ambient environment. Diethylhexyl phthalate (DEHP), for example, closely resembles organochlorine pesticides (DDT, PCB) in rate of uptake, storage, and biomagnification in a variety of aquatic organisms (9) .
The U.S. Department of Health and Human Services, particularly the Food and Drug Administration (4, 10) and the National Institute of Environmental Health Sciences (11) (12) (13) has, therefore, a continuing interest and concern regarding the safety of phthalates. This concern is reflected in the sponsoring of conferences on phthalate esters in 1972 (3, 4, 9, 13) and in 1981. Several reviews (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) presented the toxicity of phthalate esters. Although DMEP has been shown to be one of the most toxic phthalates, little is known regarding the teratogenicity caused by a single maternal injection of DMEP during the organogenetic period in the rat.
Dietary supplementation of zinc has prevented teratogenic effects in rats induced by the maternal administration of a chelating agent, ethylenediaminetetraacetic acid (24) . Dietary deprivation of zinc, on the other hand, could induce embryopathic and teratogenic effects in the rat, which was otherwise resistant to the teratogenicity of EM-12, a stable analog ofthalidomide (25) . Although phthalate esters bear similarities to thalidomide in inducing congenital malformations in the chick embryo (26) , the role of zinc, if any, in phthalate-induced teratogenicity has not been reported.
Metabolism studies on phthalates using radiotracer techniques have been conducted in adult rats (27) (28) (29) (30) (31) Rats were injected intravenously on day 13 of gestation with 1C-DMEP or physiological saline at 0.6 ml/kg body weight, and the animals were sacrificed by decapitation at 1 and 4 hr after treatment. Each treatment group had three animals. Placentae and fetuses were dissected out. For measurement of total phthalate concentration, pooled portions of placental (0.33 ± 0.10 g) and fetal tissues (0.50 0.12 g) were dissolved in 1 ml Soluene and 10 ml of Instagel (both obtained from Packard Instrument Co.). For acid and neutral extractions of DMEP, portions of the placentae (0.40 ± 0.08 g) and the fetuses (0.42 ± 0.18 g) were homogenized with 1 ml of 0.9% NaCl in a ground glass homogenizer. The homogenates were extracted three times with ethyl acetate (2.5 ml). The extractions were separated into organic and aqueous phases by centrifugation (4000 g, 5 min). The residual aqueous phase was acidified to pH 1.0 with 2N H2SO4 and then reextracted with ethyl acetate. The neutral and acid extracts were made to 10 ml with ethyl acetate. A portion (5 ml) of each extract was transferred to a scintillation vial and was evaporated under a stream of N2 at 37°C to a volume of -1 ml before adding 10 ml of Instagel for counting. The chemiluminescence of the samples was minimized by storing the samples in a dark, cold storage room for 4-7 days. 91 Counts, counting efficiency, and the original weight of the sample were used to calculate the radioactivity of each specimen in terms of disintegrations per minute per gram of tissue. These values were used in conjunction with specific activity of injected '4C-DMEP to estimate molar concentrations of the teratogen in the fetus and the placenta.
Statistical Procedures
The reduction in mean fetal weight following administration of DMEP was compared with the normal saline controls by using Dunnett's procedure (41) . Chi-square with Yates's continuity correction (42) was used to test the hypothesis that the percentages of dead and/or resorbed fetuses are equal in treatment and control groups and to compare the percentages of skeletally malformed fetuses with the control. Since the expected frequencies of the congenital deformities of the brain were small, Fisher's exact test was used to test these data. Student's t-test was used to compare the mean uptake of 65Zn by and the Zn content of the placentae and the fetuses.
Results
Embryopathy, Fetotoxicity and Teratogenicity of DMEP Maternal administration of DMEP in rats caused a significant (p < 0.01) reduction in the mean weight of living fetuses as compared to the corresponding value for the physiological saline-treated controls (Table 1) . A single injection of DMEP induced a pronounced (p < 0.01) fetotoxicity during the organogenetic period regardless of the day of injection. The fetotoxic (Table 1 ) and the embryopathic (Table  2 ) effects were greater during the early stages (days 10 or 11 of gestation) of organogenesis than during the later stages (days 12, 13 or 14 of gestation).
Embryopathic effects were evaluated by percentage of dead and resorbed fetuses ( Table 2) . Reproductive toxicity of DMEP, in this regard, was four to seven times higher upon injection on day 10 of gestation as compared to days [11] [12] [13] [14] ; 79% of the fetuses were dead and resorbed following maternal administration of DMEP on day 10 . Intraperitoneal administration of normal saline to pregnant rats resulted in fetal death and resorptions in 7.6% of fetuses.
In comparison to controls, DMEP induced higher rates of congenital deformities of the brain. None of the fetuses from the control group exhibited hydro- (22) . A significant (p < 0.01) reduction in fetal weight (Table 1) has also been observed with other phthalate esters such as DEHP and dibutyl phthalate in rats (43) and in mice (44) .
DMEP has been shown to be the most embryo-and fetotoxic member of the phthalate ester family (3, 16, 20) . In part, this may be due to its high aqueous solubility compared to other phthalate esters, although the aqueous solubility of all phthalate esters is extremely low. DMEP, for example, is about 143 times (0.73 ml/100 ml H20) more soluble in water than DEHP (0.0051 ml/100 ml H20) and is the most soluble phthalate ester (3, 21) . Fetal deaths and resorptions caused by DMEP were as high as 79% upon a single injection on day 10 of gestation (Table  2) .
Congenital malformations of the brain involving hydrocephalus interna similar to those caused by DMEP (Table 3 ) have also been induced by dietary deficiency of zinc in rats (45) (46) (47) (48) (49) (50) (51) . This is the first report to document hydrocephaly caused by the maternal administration of DMEP in rats.
Phthalate esters have been studied for their congenital skeletal dysmorphogenetic effects in rodents, but in this regard, these studies are the first to report skeletal malformations following a single injection of DMEP. Phthalate esters are considered compounds related to thalidomide (26) . Congenital multiple skeletal malformations and appendicular dysmorphogenesis, which are considered "typical" of the thalidomide syndrome (39), have been difficult to produce in rats. These studies are the first, however, to report congenital multiple skeletal malformations and appendicular dysmorphogenesis following maternal administration of DMEP. Congenital multiple skeletal malformations upon a single intravenous maternal administration of thalidomide were also reported in our laboratory for the first time (52) .
Intraperitoneal administration of sterile normal saline to pregnant animals resulted in some dead and resorbed fetuses and also caused skeletal malformations in control animals. Such effects have been reported earlier (53) . The reproductive toxicity of DMEP, however, was several times higher than the normal saline control. The teratogenic effects of DMEP reported here have greater significance than the results where teratogenicity of phthalates is compared to untreated controls (22) .
The malformations reported here are several hundredfold higher than the sporadic malformations found in rats, and are, therefore, due to the teratogenicity of DMEP. Major skeletal malformations in rats occur at a frequency of 0.41% (54), while those caused by DMEP were 161-234 times higher than this background level (Table 4) . Craniofacial organ deformities such as hydrocephaly occur sporadically in rats at a frequency of 0.0506% (54) , while DMEP induced this CNS malformation (Table 3) in 13-26% of the fetuses (257-514 times higher than the sporadic occurrence).
Role of Zinc in DMEP-Induced Teratogenesis
The conclusion that DMEP alters zinc metabolism in rats is based upon significantly (p -0.01) decreased zinc content in the fetuses of DMEPtreated rats as compared to that in the controls (Fig. 2) .
Pregnant rats cannot mobilize zinc sufficiently from their body stores including that from the liver and bone (50, 51) , to supply the needs of their fetuses. As a result of this insufficient zinc supply, a transient deficiency of zinc may have been produced following DMEP administration which, in turn, is reflected by the decreased zinc content in the fetal tissue. The teratogenic effects reported here are in agreement with those caused by the decreased zinc content in fetuses when rats were placed on zincdeficient diets during gestation (51) .
Permeability of the placenta to zinc increases after day 18 of gestation (55 (24) . Singh et al. (32) reported that first order kinetics describe the elimination of 14C-labeled phthalates from maternal blood, amniotic fluid and fetal tissue with time. Also, zinc (59) and phthalates (32) follow, in general, a similar time course and concentration kinetics in maternal blood plasma and fetal tissue. Therefore, the authors propose a role of zinc in DMEP-induced teratogenesis in rats.
The reduced content of zinc in the target organ, the fetus (Fig. 2) , following administration of DMEP, may be due to the rapid turnover rate of zinc following administration of phthalates (57, 58) . Coadministration of zinc was found to offer a substantial measure of protection against testicular atrophy and loss of organ weight caused by dibutyl phthalate (57) .
The protective effect, if any, of coadministration of zinc and the underlying mechanism of zinc against the fetotoxic and teratogenic effects of DMEP is unknown, as is the protective mechanism of zinc therapy in phthalate-induced testicular atrophy. There are many common parallels, however, between congenital abnormalities caused by zinc deficiency in rats (45, 47-50, 60, 61) and those produced by DMEP (Tables 1-4) . These include the manifestation of fetotoxicity by a marked reduction in fetal weight (Table 1) ; embryopathy by fetal resorption ( (Table 3) ; and skeletal malformations ( Table 4 ). The incidence of hydrocephalus interna produced by DMEP (Table 3 ) was similar to that produced by maternal zinc deficiency (51, 60, 61) , although, in general, its severity was much less.
Fetoplacental Metabolism of 14C-DMEP Although no specific study has been reported which identifies the nature of DMEP or its metabolites in the rat fetus or placenta, the results reported here are in general agreement (28) (29) (30) (31) (32) 62) with the metabolism of phthalates in nonpregnant rats as obtained by using radiotracer techniques.
There is a relationship between teratogenicity and carcinogenicity (63) . Such a relationship for DMEP, is not unequivocally established. Although further studies are required to confirm whether or not DMEP is a carcinogen, there are examples of a carcinogen having teratogenic potential and a teratogen having carcinogenic potential (63) . This is so because congenital malformations occur through genetic defects, or through embryotoxic effects on prenatal development, or both. For example, methotrexate has carcinogenic properties and possesses teratogenic potential, while 6-mercaptopurine, cyclophosphamide, and nitrosamides are teratogenic and have carcinogenic potential (63) . Several researchers (3, 10, 12, 16, 26, 64, 65) have therefore cautioned about the toxicity and possible health threats of phthalates.
Conclusions
The studies described here establish that the maternal administration of dimethoxyethyl phthalate (DMEP) in a single dose during the organogenetic period (days [10] [11] [12] [13] [14] in the rat causes: (a) embryopathic, fetotoxic and teratogenic effects several times higher than reported by the widely studied plasticizer, diethylhexyl phthalate (DEHP); (b) congenital deformities of the brain, such as hydrocephalus interna; (c) congenital skeletal malformations (66-96%), including multiple skeletal (14-64%) and appendicular deformities (25-57%); (d) adverse effects on maternal-fetal metabolism of zinc; and (e) teratogenicity, as mentioned above, due to DMEP in the fetus. 
